骨科

订阅

MedSci主页 / 所有栏目 / 骨科

Sci Transl Med：Thy-1（CD90）可促进骨形成并抑制脂肪形成

2018-08-18 MedSci MedSci原创

关注

骨质疏松症和肥胖症是由于成骨和成脂分化受到干扰，为老龄化社会带来了新的挑战。由于Thy-1在间充质衍生的成纤维细胞中的调节作用，我们研究了Thy-1表达对成骨和成脂分化之间的间充质干细胞（MSCs）分化的影响以及体内骨形成和脂肪组织发育的影响。结果显示，与野生型小鼠的MSCs相比，Thy-1缺陷型小鼠的MSCs的成骨细胞分化降低，脂肪形成分化增加。同样的是，Thy-1缺陷型小鼠的骨量和骨形成率降低

骨质疏松症和肥胖症是由于成骨和成脂分化受到干扰，为老龄化社会带来了新的挑战。由于Thy-1在间充质衍生的成纤维细胞中的调节作用，我们研究了Thy-1表达对成骨和成脂分化之间的间充质干细胞（MSCs）分化的影响以及体内骨形成和脂肪组织发育的影响。

结果显示，与野生型小鼠的MSCs相比，Thy-1缺陷型小鼠的MSCs的成骨细胞分化降低，脂肪形成分化增加。同样的是，Thy-1缺陷型小鼠的骨量和骨形成率降低，皮质孔隙率升高，导致骨强度降低。同时，体重，皮下/表皮脂肪量和骨脂肪量增加。Thy-1缺乏伴随着特异性Wnt配体的表达降低，同时Wnt抑制剂硬化蛋白和dickkopf-1的表达增加，对Wnt的响应性改变。我们证实了肥胖患者骨质疏松症和骨骼组织失调的干扰骨重建反映了血清Thy-1浓度的降低。

综上所述，该研究结果为骨形成和肥胖的相互调节提供了新的见解，并开辟了新的视角来监测和干预肥胖和骨质疏松症中脂肪生成和成骨的平衡失调。

原始出处：

Picke AK1, Campbell GM, et al., Thy-1 (CD90) promotes bone formation and protects against obesity. Sci Transl Med. 2018 Aug 8;10(453). pii: eaao6806. doi: 10.1126/scitranslmed.aao6806.

版权声明：
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料，版权均属于梅斯医学所有。非经授权，任何媒体、网站或个人不得转载，授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章，或“梅斯号”自媒体发布的文章，仅系出于传递更多信息之目的，本站仅负责审核内容合规，其内容不代表本站立场，本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系，我们将立即进行删除处理。
在此留言
评论区 (3)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=2067371, encodeId=db1b206e3710a, content=<a href='/topic/show?id=d0841e75535' target=_blank style='color:#2F92EE;'>#Transl#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=20, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17755, encryptionId=d0841e75535, topicName=Transl)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdqq.qlogo.cn/qqapp/101173734/363C99735735B7F4CB11D5F78F580525/100, createdBy=aab22500211, createdName=ms3025846204744509, createdTime=Wed May 15 02:32:00 CST 2019, time=2019-05-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1657054, encodeId=5ada165e054c4, content=<a href='/topic/show?id=3ca31e71903' target=_blank style='color:#2F92EE;'>#TRA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17719, encryptionId=3ca31e71903, topicName=TRA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=757b24868428, createdName=bsmagic9140, createdTime=Wed Sep 26 14:32:00 CST 2018, time=2018-09-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1609068, encodeId=d4a61609068ba, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=16, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Mon Aug 20 07:32:00 CST 2018, time=2018-08-20, status=1, ipAttribution=)]
    2019-05-15 ms3025846204744509

    #Transl#

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=2067371, encodeId=db1b206e3710a, content=<a href='/topic/show?id=d0841e75535' target=_blank style='color:#2F92EE;'>#Transl#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=20, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17755, encryptionId=d0841e75535, topicName=Transl)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdqq.qlogo.cn/qqapp/101173734/363C99735735B7F4CB11D5F78F580525/100, createdBy=aab22500211, createdName=ms3025846204744509, createdTime=Wed May 15 02:32:00 CST 2019, time=2019-05-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1657054, encodeId=5ada165e054c4, content=<a href='/topic/show?id=3ca31e71903' target=_blank style='color:#2F92EE;'>#TRA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17719, encryptionId=3ca31e71903, topicName=TRA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=757b24868428, createdName=bsmagic9140, createdTime=Wed Sep 26 14:32:00 CST 2018, time=2018-09-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1609068, encodeId=d4a61609068ba, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=16, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Mon Aug 20 07:32:00 CST 2018, time=2018-08-20, status=1, ipAttribution=)]
    2018-09-26 bsmagic9140

    #TRA#

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=2067371, encodeId=db1b206e3710a, content=<a href='/topic/show?id=d0841e75535' target=_blank style='color:#2F92EE;'>#Transl#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=20, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17755, encryptionId=d0841e75535, topicName=Transl)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdqq.qlogo.cn/qqapp/101173734/363C99735735B7F4CB11D5F78F580525/100, createdBy=aab22500211, createdName=ms3025846204744509, createdTime=Wed May 15 02:32:00 CST 2019, time=2019-05-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1657054, encodeId=5ada165e054c4, content=<a href='/topic/show?id=3ca31e71903' target=_blank style='color:#2F92EE;'>#TRA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17719, encryptionId=3ca31e71903, topicName=TRA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=757b24868428, createdName=bsmagic9140, createdTime=Wed Sep 26 14:32:00 CST 2018, time=2018-09-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1609068, encodeId=d4a61609068ba, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=16, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Mon Aug 20 07:32:00 CST 2018, time=2018-08-20, status=1, ipAttribution=)]
    2018-08-20 ms3994565386320060

    #Med#

    0